Pharma Insider Nabbed! Made $10K on Secret Deal!

SEC v. Weiguo Zhai — U.S. Securities and Exchange Commission Litigation Release No. 26581, dated July 9, 2026.

The SEC charged Weiguo Zhai, a former employee of AstraZeneca Pharmaceuticals LP, with insider trading. Zhai illegally purchased shares of Icosavax Inc. before its acquisition by AstraZeneca was publicly announced, using confidential information obtained through his employment. He realized illicit profits of $10,006 and agreed to pay disgorgement, prejudgment interest, and a civil penalty.

In Plain English

Imagine you work for a big company that's planning to buy a smaller company. You find out about this secret plan before anyone else. You then secretly buy stock in the smaller company, hoping its price will go up when the news comes out. That's exactly what Weiguo Zhai did. He used his inside knowledge to buy stock and made money illegally.

Disclaimer: all facts are drawn from the SEC's own filings; the claims described are allegations unless and until a court rules or the parties settle, and some cases end in dismissal.

How the Alleged Scheme Worked

1. Access to Confidential Information Weiguo Zhai worked as a Senior Director of Research and Development at AstraZeneca Pharmaceuticals LP. In November and December 2023, he was part of the due diligence team evaluating a potential acquisition of Icosavax Inc. by AstraZeneca.
2. Violation of Company Policy Zhai was aware of and subject to AstraZeneca's policies, including a confidentiality agreement and a 'Global Standard: Dealing in AstraZeneca Securities.' These policies prohibited employees with access to confidential information from trading in the securities of other companies, especially potential acquisition targets.
3. Misappropriation of Information Despite these policies, Zhai used the confidential information about the impending Icosavax transaction that he acquired through his position at AstraZeneca.
4. Illegal Stock Purchases Before the public announcement of the acquisition, Zhai purchased 1,000 shares of Icosavax stock in his own brokerage account and another 1,000 shares in his wife's brokerage account.
5. Public Announcement and Stock Increase On December 12, 2023, Icosavax publicly announced that AstraZeneca PLC would acquire it through a tender offer. Following this announcement, Icosavax's stock price increased by approximately 49.48%.
6. Realization of Illicit Profits Based on these trades, Zhai realized aggregate illicit profits totaling $10,006.

The Enforcement Action

On July 8, 2026, the SEC filed a settled action against Weiguo Zhai for insider trading. Zhai, a former employee of AstraZeneca Pharmaceuticals LP, was charged with illegally trading securities of Icosavax Inc. before the public announcement of its acquisition by AstraZeneca. The SEC alleged Zhai misappropriated confidential information to purchase 2,000 shares of Icosavax stock, realizing $10,006 in illicit profits. Zhai consented to a final judgment permanently enjoining him from violating Sections 10(b) and 14(e) of the Securities Exchange Act of 1934 and Rules 10b-5 and 14e-3 thereunder. The judgment also orders Zhai to pay $10,006 in disgorgement, $1,535 in prejudgment interest, and a $10,006 civil penalty.

Named in this action: Weiguo Zhai.

Original SEC litigation release ↗ · Browse all cases